Drugs

, Volume 71, Issue 11, pp 1397–1412 | Cite as

Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

Review Article

Abstract

Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge. Currently, the only drugs that are US FDA approved to treat this subset of patients are paclitaxel, pegylated liposomal doxorubicin (PLD) and topotecan. The response rates with these agents is in the 10–15% range and overall survival is around 12 months. Other drugs that have shown some activity in platinum-resistant ovarian cancer include the taxane analogues, oral etoposide, pemetrexed and bevacizumab. Unfortunately, randomized phase III trials of second-line chemotherapy in patients with platinum-resistant ovarian cancer have not shown an advantage over existing therapy with respect to progression-free survival or overall survival. The only trial that has reported a significant progression-free survival advantage over standard therapy is a randomized phase II trial of PLD with or without EC145, a folate-linked vinca alkaloid. Final survival results of this trial are pending.

References

  1. 1.
    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010 Sep–Oct; 60(5): 277–300PubMedCrossRefGoogle Scholar
  2. 2.
    Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991 Mar; 9(3): 389–93PubMedGoogle Scholar
  3. 3.
    Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006 May 1; 106(9): 1933–9PubMedCrossRefGoogle Scholar
  4. 4.
    Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006 Dec; 13(12): 1702–10PubMedCrossRefGoogle Scholar
  5. 5.
    McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989 Aug 15; 111(4): 273–9PubMedGoogle Scholar
  6. 6.
    Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994 Sep; 12(9): 1748–53PubMedGoogle Scholar
  7. 7.
    Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995 Apr 13; 332(15): 1004–14PubMedCrossRefGoogle Scholar
  8. 8.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophos-phamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 Jan 4; 334(1): 1–6PubMedCrossRefGoogle Scholar
  9. 9.
    Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006 Jun; 101(3): 436–40PubMedCrossRefGoogle Scholar
  10. 10.
    Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009 Oct 17; 374(9698): 1331–8PubMedCrossRefGoogle Scholar
  11. 11.
    Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002; 41(5): 418–24PubMedCrossRefGoogle Scholar
  12. 12.
    ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997 Jun; 15(6): 2183–93Google Scholar
  13. 13.
    ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004 Jan; 15(1): 100–3CrossRefGoogle Scholar
  14. 14.
    Gore M, ten Bokkel Huinink W, Carmichael J, et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001 Apr 1; 19(7): 1893–900PubMedGoogle Scholar
  15. 15.
    Frykman G, Williams G, Pazdur R. Conflicting phase II efficacy data for Doxil. J Clin Oncol 2001 Jan 15; 19(2): 596–7PubMedGoogle Scholar
  16. 16.
    Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000 Sep; 18(17): 3093–100PubMedGoogle Scholar
  17. 17.
    Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997 Mar; 15(3): 987–93PubMedGoogle Scholar
  18. 18.
    Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004 Oct; 95(1): 1–8PubMedCrossRefGoogle Scholar
  19. 19.
    Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 Jul 15; 19(14): 3312–22PubMedGoogle Scholar
  20. 20.
    Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998 Feb; 16(2): 405–10PubMedGoogle Scholar
  21. 21.
    Manetta A, Blessing JA, Hurteau JA. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group. Gynecol Oncol 1998 Jan; 68(1): 45–6PubMedCrossRefGoogle Scholar
  22. 22.
    Markman M, Blessing JA, Moore D, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998 Jun; 69(3): 226–9PubMedCrossRefGoogle Scholar
  23. 23.
    Plaxe SC, Blessing JA, Morgan MA, et al. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Am J Clin Oncol 2002 Feb; 25(1): 45–7PubMedCrossRefGoogle Scholar
  24. 24.
    Fracasso PM, Brady MF, Moore DH, et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 2001 Jun 15; 19(12): 2975–82PubMedGoogle Scholar
  25. 25.
    Hoffman MA, Blessing JA, Morgan M. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000 Dec; 79(3): 463–5PubMedCrossRefGoogle Scholar
  26. 26.
    Markman M, Blessing JA, DeGeest K, et al. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial. Gynecol Oncol 1999 Dec; 75(3): 444–6PubMedCrossRefGoogle Scholar
  27. 27.
    Miller DS, Blessing JA, Waggoner S, et al. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2005 Jan; 96(1): 67–71PubMedCrossRefGoogle Scholar
  28. 28.
    Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003 Feb; 88(2): 130–5PubMedCrossRefGoogle Scholar
  29. 29.
    Fracasso PM, Blessing JA, Morgan MA, et al. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol 2003 Aug 1; 21(15): 2856–9PubMedCrossRefGoogle Scholar
  30. 30.
    Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006 Nov; 103(2): 446–50PubMedCrossRefGoogle Scholar
  31. 31.
    De Geest K, Blessing JA, Morris RT, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol Jan 1; 28 (1): 149–53Google Scholar
  32. 32.
    Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009 Jun 1; 27(16): 2686–91PubMedCrossRefGoogle Scholar
  33. 33.
    Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2011 Jul; 122(1): 111–5PubMedCrossRefGoogle Scholar
  34. 34.
    Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Nat Cancer Inst 2004 Nov 17; 96(22): 1682–91PubMedCrossRefGoogle Scholar
  35. 35.
    Tinker AV, Gebski V, Fitzharris B, et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel: ANZGOG 02-01. Gynecol Oncol 2007 Mar; 104(3): 647–53PubMedCrossRefGoogle Scholar
  36. 36.
    Berkenblit A, Seiden MV, Matulonis UA, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 2004 Dec; 95(3): 624–31PubMedCrossRefGoogle Scholar
  37. 37.
    Swensen RE, Childs J, Higgins D, et al. A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer [abstract no. 5020]. J Clin Oncol 2011 Jun 9; 29 (15 Suppl.)Google Scholar
  38. 38.
    Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Sem Oncol 1999 Apr; 26 (2 Suppl. 6): 42–7Google Scholar
  39. 39.
    Miotti S, Bagnoli M, Ottone F, et al. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem 1997 Jun 15; 65(4): 479–91PubMedCrossRefGoogle Scholar
  40. 40.
    Hurteau JA, Blessing JA, DeCesare SL, et al. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2001 Jul; 82(1): 7–10PubMedCrossRefGoogle Scholar
  41. 41.
    Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohisto-chemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 2005 Aug 1; 11(15): 5539–48PubMedCrossRefGoogle Scholar
  42. 42.
    Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007 Nov 20; 25(33): 5165–71PubMedCrossRefGoogle Scholar
  43. 43.
    Schilder RJ, Sill MW, Lee RB, et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2008 Jul 10; 26(20): 3418–25PubMedCrossRefGoogle Scholar
  44. 44.
    Matei D, Sill M, DeGeest K, et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study [abstract no. 5537]. J Clin Oncol 2008; 26 (15 Suppl.)Google Scholar
  45. 45.
    Modesitt SC, Sill M, Hoffman JS, et al. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008 May; 109(2): 182–6PubMedCrossRefGoogle Scholar
  46. 46.
    Behbakht K, Sill M, Darcy KM, et al. Phase II trial of the mTOR inhibitor temsirolimus and evaluation of circulating tumor cells in persistent or recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study [abstract no. 7]. Gynecol Oncol 2010; 116 (3)Google Scholar
  47. 47.
    Usha L, Sill M, Darcy KM, et al. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor enzastaurin and evaluation of markers with potential predicitive and prognostic value in persistent or recurrent epithelial ovarian and promary peritoneal malignancies [abstract 37]. Gynecol Oncol 2010; 116 Suppl. 1CrossRefGoogle Scholar
  48. 48.
    Rocereto TF, Brady WE, Shahin MS, et al. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010 Mar; 116(3): 332–4PubMedCrossRefGoogle Scholar
  49. 49.
    Sabbatini P, Sill MW, O’Malley D, et al. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol 2008 Dec; 111(3): 455–60PubMedCrossRefGoogle Scholar
  50. 50.
    Kavanagh JJ, Sill MW, Ramirez PT, et al. Phase II multi-center open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2008 May–Jun; 18(3): 460–4PubMedCrossRefGoogle Scholar
  51. 51.
    Monk BJ, Sill MW, Hanjani P, et al. Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group [abstract no. 5046]. J Clin Oncol 2010; 28 (15 Suppl.)Google Scholar
  52. 52.
    Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009 Mar 20; 27(9): 1419–25PubMedCrossRefGoogle Scholar
  53. 53.
    Bolis G, Parazzini F, Scarfone G, et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 1999 Jan; 72(1): 60–4PubMedCrossRefGoogle Scholar
  54. 54.
    Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000 Mar; 18(6): 1193–202PubMedGoogle Scholar
  55. 55.
    Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 2004 Jun 1; 90(11): 2112–7PubMedGoogle Scholar
  56. 56.
    Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007 Jul 1; 25(19): 2811–8PubMedCrossRefGoogle Scholar
  57. 57.
    Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008 Feb 20; 26(6): 890–6PubMedCrossRefGoogle Scholar
  58. 58.
    Meier W, du Bois A, Reuss A, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy: a prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2009 Aug; 114(2): 199–205PubMedCrossRefGoogle Scholar
  59. 59.
    Vergote I, Finkler N, del Campo J, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009 Sep; 45(13): 2324–32PubMedCrossRefGoogle Scholar
  60. 60.
    Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010 Jul 1; 28(19): 3107–14PubMedCrossRefGoogle Scholar
  61. 61.
    Naumann RW, Symanowski JT, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer [abstract no. LBA5012b]. J Clin Oncol 2010; 28 (18 Suppl.)Google Scholar
  62. 62.
    Colombo N, Schwartz PE, Bamias A, et al. Results of a randomized, open-label, phase III trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian or peritoneal cancer. Ann Oncol 2010; 21 Suppl. 8CrossRefGoogle Scholar
  63. 63.
    Kavanagh JJ, Gershenson DM, Choi H, et al. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer 2005 Jul–Aug; 15(4): 593–600PubMedCrossRefGoogle Scholar
  64. 64.
    Monk B, Herzog T, Kaye S, et al. Final survival results of the randomized phase II study of trabectedin with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin in recurrent ovarian cancer [abstract no. 5046]. J Clin Oncol 2011; 29 Suppl.Google Scholar
  65. 65.
    Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 2011 Jun 9; 29 (15 Suppl.): 5045Google Scholar
  66. 66.
    Jurado JM, Sanchez A, Pajares B, et al. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 2008 Sep; 10(9): 583–6PubMedCrossRefGoogle Scholar
  67. 67.
    Smerdel MP, Steffensen KD, Waldstrom M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010 Aug 1; 118(2): 167–71PubMedCrossRefGoogle Scholar
  68. 68.
    Tillmanns TD, Lowe MP, Schwartzberg MS, et al. A phase II study of bevacizumab with nab-paclitaxel in patients with reucrrent, platinum-resistant primary epithelial ovarian or peritoneal carcinoma [abstract no. 5009]. J Clin Oncol 2010; 28 (15 Suppl.)Google Scholar
  69. 69.
    Hoffmann-La Roche. AURELIA: A study of avastin (bevacizumab) added to chemotherapy in patients with platinum-resistant ovarian cancer [ClinicalTrials.gov identifier NCT00976911]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00976911 [Accessed 2011 Jun 28]
  70. 70.
    Karlan BY, Oza AM, Hansen L, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian carcinoma [abstract no. 5000]. J Clin Oncol 2010; 28 (15 Suppl.)Google Scholar
  71. 71.
    Coleman RL, Duska LR, Ramirez PT, et al. Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer [abstract]. J Clin Oncol 2011 Jun 9; 29 (15 Suppl.): 5017Google Scholar
  72. 72.
    Matei D, Shen C, Fang F, et al. A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC) [abstract]. J Clin Oncol 2011 Jun 9; 29 (15 Suppl.): 5011CrossRefGoogle Scholar
  73. 73.
    Armstrong DK, Bicher A, Coleman RL, et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer [abstract no. 5500]. J Clin Oncol 2008; 26 (15 Suppl.)Google Scholar
  74. 74.
    Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22(15): 3120–5PubMedCrossRefGoogle Scholar
  75. 75.
    Spannuth WA, Lyn YG, Merritt WM, et al. Therapeutic efficacy of folate receptor alpha blockade with MORAb-003 in ovarian cancer. Gynecol Oncol 2008; 108 (3 Suppl. 1): S135Google Scholar
  76. 76.
    Elit L, Konner JA, Armstrong DK, et al. A randomized, double-blind placebo-controlled phase III study of the efficacy and safety of arletuzumab (MORab-003) incombinatin with weekly paclitaxel in subjects with platinum-resistnat or refractory relapsed ovarian cancer [abstract no. TPS255]. J Clin Oncol 2010; 28 (15 Suppl.)Google Scholar
  77. 77.
    Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010 May 20; 28(15): 2512–9PubMedCrossRefGoogle Scholar
  78. 78.
    Birrer MJ, Konstantinopoulos P, Penson RT, et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer [abstract]. J Clin Oncol 2011 Jun 9; 29 (15 Suppl.): 5005Google Scholar
  79. 79.
    Nishimura S, Tsuda H, Hashiguchi Y, et al. Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis. Int J Gynecol Cancer 2007 Jan–Feb; 17(1): 159–63PubMedCrossRefGoogle Scholar
  80. 80.
    Germano D, Rosati G, Manzione L. Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience. J Chemother 2007 Oct; 19(5): 577–81PubMedGoogle Scholar
  81. 81.
    Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [published erratum appears in J Clin Oncol 2008 Apr 1; 26 (10): 1773]. J Clin Oncol 2007 Nov 20; 25(33): 5180–6PubMedCrossRefGoogle Scholar
  82. 82.
    Strauss HG, Hemsen A, Karbe I, et al. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Antic-ancer Drugs 2008 Jun; 19(5): 541–5CrossRefGoogle Scholar
  83. 83.
    Ray-Coquard I, Weber B, Cretin J, et al. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer 2009 Feb 24; 100(4): 601–7PubMedCrossRefGoogle Scholar
  84. 84.
    Gupta D, Owers RL, Kim M, et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol 2009 Jun; 113(3): 327–30PubMedCrossRefGoogle Scholar
  85. 85.
    Itani Y, Hosokawa K, Ito K, et al. A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer. Anticancer Res 2009 May; 29(5): 1521–6PubMedGoogle Scholar
  86. 86.
    Pectasides D, Pectasides E, Papaxoinis G, et al. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel-pretreated ovarian carcinoma. Gynecol Oncol 2010 Jul; 118(1): 52–7PubMedCrossRefGoogle Scholar
  87. 87.
    Vergote IB, Micha JP, Pippitt CH, et al. Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer [abstract]. J Clin Oncol 2010; 28 (15 Suppl.): 5012Google Scholar
  88. 88.
    Food and Drug Administration. NDA 22-447 ODAC briefing document: Yondelis (trabectidin) [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM171149.pdf [Accessed 2011 Jun 13]
  89. 89.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 Jan; 45(2): 228–47PubMedCrossRefGoogle Scholar
  90. 90.
    Bast RC, Thigpen JT, Arbuck SG, et al. Clinical trial end-points in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 2007 Nov; 107(2): 173–6PubMedCrossRefGoogle Scholar
  91. 91.
    Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000 Jan; 18(1): 106–15PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Carolinas Medical CenterCharlotteUSA
  2. 2.MD Anderson Cancer CenterUniversity of TexasHoustonUSA

Personalised recommendations